Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer. Immunohistochemistry studies indicate that YAP expression is associated with poor clinical outcomes in patients. Overexpression or constitutive activation of YAP leads to transformation and tumorigenesis in human ovarian surface epithelial cells, and promotes growth of cancer cells in vivo and in vitro. YAP induces expression of EGF receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2). HBEGF or NRG1, in turn, activates YAP and stimulates cancer cell growth. Knockdown of ERBB3 or HBEGF eliminates YAP effects on cell growth and transformation, while knockdown of YAP abrogates NRG1-and HBEGF-stimulated cell proliferation. Collectively, our study demonstrates the existence of HBEGF&NRGs/ERBBs/YAP/HBEGF&NRGs autocrine loop that controls ovarian cell tumorigenesis and cancer progression.
INTRODUCTION
functional mechanism of YAP on ovarian tumorigenesis and ovarian cancer progression are not fully understood.
The actin cytoskeleton or cellular tension appears to be the master mediator that integrates and transmits upstream signals to the core Hippo signaling cascade. 6 , 15 It has been proposed that activation of epidermal growth factor receptors (EGFR) promotes cell growth by changing cell polarity, affecting cell mechanotransduction and overcoming cell contact inhibition. 16 -18 Indeed, studies have demonstrated that EGF stimulates YAP activity in Drosophila and MCF-10A cells, which contributes to cell proliferation. 19 , 20 However, other studies have shown that EGF has no significant effect on YAP phosphorylation 21 , 22 .
Therefore, the role of the EGFR signaling pathway on the regulation of YAP activity remains unclear. Whether the activation of EGFR family of tyrosine kinase receptors (ERBB) and the Hippo/YAP signaling pathway interact with each other to regulate ovarian cancer progression has not been investigated.
In the present study, we examine the relationship between YAP expression and the clinicopathological outcomes of ovarian cancer with large cohort of patient samples, and determine the role of YAP in the initiation and progression of ovarian cancer in vitro and in vivo. Our results show that the expression of YAP is associated with poor prognosis of ovarian cancer patients. Overexpression of YAP is sufficient to induce transformation of immortalized human ovarian surface epithelial cells (HOSE) and to initiate formation of ovarian tumors in vivo. Our mechanistic studies reveal the existence of an HBEGF & NRGs/ ERBB3/YAP/HBEGF & NRGs positive feedback loop, which may play a critical role in regulating the development and progression of ovarian cancer.
RESULTS

YAP expression is associated with poor prognosis in human ovarian cancer
To clarify the association between YAP expression and clinical outcomes of ovarian cancer patients, we quantified the expression of YAP in 42 normal human ovarian tissues and 342 ovarian cancer tissues by immunohistochemistry (IHC). The YAP immunosignal was low or undetectable in normal ovarian samples (Fig. 1a, 1d ). In contrast, YAP levels were significantly increased in the tumor tissues, with higher level in advanced stage ovarian cancer samples (Fig. 1a-1d ). Both positivity and intensity of the YAP immunosignals were associated with the progression of ovarian cancer (Fig. 1b& 1c) . YAP immunostaining was primarily detected in the nucleus of cancer cells (Fig. 1d ).
To determine whether YAP expression is associated with patient survival, overall survival data of patients with ovarian cancer were stratified into two groups (low & high) based on the intensity of YAP immunosignal. Kaplan-Meier survival estimation indicated that higher YAP levels were significantly associated with poor patient overall survival (p = 0.018) (Fig.  1e) . Additionally, the positivity of YAP staining significantly correlated with the primary tumor ( Fig. 1f) , regional lymph nodes status (Fig. 1g) , and tumor metastasis ( 
YAP promotes proliferation of normal and cancerous ovarian cells in vitro
We prepared six human cell lines with differential YAP levels and activities to determine the effect of YAP on the proliferation of normal and cancerous ovarian cells. HOSE-YAP S127A and TOV21G-YAP S127A cell lines express constitutively activated YAP1. HOSE-YAP and TOV21G-YAP overexpress wild-type YAP1. HOSE-MXIV and TOV21G-MXIV cells were transfected with empty vectors (MXIV) and used as controls. Western blot analysis showed that YAP was successfully overexpressed in HOSE-YAP, TOV21G-YAP, HOSE-YAP S127A and TOV21G-YAP S127A cells (Fig. 2a& 2b) . YAP in HOSE-YAP S127A , and TOV21G-YAP S127A cells were constitutively activated, which is indicated by the low level of phosphorylated YAP (Fig. 2a& 2b) . Consistent with Western blot results, HOSE-YAP, TOV21G-YAP, HOSE-YAP S127A , and TOV21G-YAP1 S127A cells continue to grow in complete medium (with 10% FBS) even after cells reached confluence; HOSE-YAP S127A and TOV21G-YAP S127A cells exhibited the highest growth rates, while cell growth in control groups slowed (TOV21G) or totally stopped after cells reached confluence (Fig. 2a&  2b) . Consistent with these results, knockdown of YAP using YAP siRNA reduced TOV21G cell proliferation (p<0.001) (Fig. 2c) . We observed that FBS suppressed YAP phosphorylation in HOSE cells (Fig. 2d ). In the FBS reduced culture medium, overexpression or constitutive activation of YAP significantly stimulated HOSE cell proliferation regardless of cell density (p<0.01) (Fig. 2e) .
In a 3D hanging drop culture system, HOSE-YAP S127A cells formed the largest spheroids after incubation for 16 days, while the HOSE-MXIV cells formed the smallest spheroids. Similarly, Ki67 was localized to almost every cells in microtissues derived from HOSE-YAP S127A cells, while it was localized to only few cells in microtissues derived from HOSE-MXIV cells (Fig. 3a) . Verteporfin 23 not only suppressed cell proliferation (supplementary Fig. S2a ), but also disrupted cell-cell communication, which was evidenced by the loose, incompletely formed spheroids and scattered distribution of cells in the culture (Fig. 3b) . TUNEL assay showed that interrupting the interaction between YAP and TEAD by addition of verteporfin to the culture also significantly increased cell apoptosis (Fig. 3c,  supplementary Fig. S2b ).
YAP is able to transform normal ovarian cancer cells and enhance anchorage-independent cancer cell growth
The Soft Agar Assay was used to determine the tumorigenicity of YAP in vitro. HOSE-T80
(HOSE) cell is an immortalized non-tumorigenic cell line. HOSE-MXIV cells, like the parental HOSE cells, formed few or no colonies on the soft agar. The HOSE-YAP and HOSE-YAP S127A cells formed many large colonies (Fig. 4a ). In particular, the HOSE-YAP S127A cells formed the majority of the colonies, indicating that colony formation was dependent on the presence of activated YAP (Fig. 4a ). Quantitative analysis showed that overexpression or constitutive activation of YAP significantly stimulated anchorage-free growth of HOSE cells (MXIV vs YAP p<0.0001; YAP vs YAP S127A p<0.05) (Fig. 4b ). In the TOV21G ovarian cancer cell line-derived cells, TOV21G-YAP and TOV21G-YAP S127A cells also formed significantly more colonies than from TOV21G-MXIV control cells (Fig.  4c& 4d, MXIV vs YAP p<0.0001; YAP vs YAP S127A p<0.001).
YAP is sufficient to induce tumorigenesis and enhance tumor growth in vivo
To confirm the oncogenic role of YAP in ovarian cells in vivo, HOSE-MXIV, HOSE-YAP, and HOSE-YAP S127A cells were injected subcutaneously into athymic nude mice. Overexpression or constitutive activation of YAP in HOSE cells was sufficient to induce tumorigenesis in 100% of the mice (ten out of ten) two weeks after cell injection (Fig. 5a ).
No tumors were observed in the HOSE-MXIV cell injected group. The tumors derived from HOSE-YAP S127A cells grew faster than tumors derived from the HOSE-YAP cells (Fig. 5a ).
To determine if YAP also enhanced cancer cell growth in vivo, TOV21G-MXIV, TOV21G-YAP, and TOV21G-YAP S127A cells were also injected subcutaneously into athymic nude mice. As expected, all three cell lines formed tumors in the athymic mice. In comparison to the controls, tumors derived from TOV21G-YAP and TOV21G-YAP S127A cells grew dramatically faster (Fig. 5b) . The tumor size and weight in these two groups were significantly increased (p< 0.001; Fig. 5c ). Immunofluorescent histochemistry analysis showed that YAP immunosignals in tumor tissues derived from TOV21G-YAP and TOV21G-YAP S127A cells were stronger than in control tissues (derived from TOV21G-MXIV cells) (Fig. 5d) . Moreover, the YAP immunosignal was primarily located to the nucleus of tumor cells (Fig. 5d) . Consistent with these results, the Ki67 immunostaining in tumor tissues derived from TOV21G-YAP and TOV21G-YAP S127A tumors was considerably greater than staining present in tumors derived from the control cell line (TOV21G-MXIV) ( Fig. 5e, supplementary Fig. S3 ).
YAP regulates expression of EGF-like ligands and ERBB receptors
Amphiregulin (AREG), an EGFR ligand, has been identified as a YAP target gene in breast epithelial cells. 24 , 25 However, overexpression of YAP did not affect AREG mRNA expression in HOSE, TOV21G and KGN cells (Fig. 6a, supplementary Fig. S4, Fig. S6 ). Instead, we found that YAP overexpression or activation drastically increased mRNA levels of two ERBB receptors, EGFR and ERBB3, and three ligands, heparin-binding EGF (HBEGF), Neuregulin-1 (NRG1) and Neuregulin-2 (NRG2) in these cell lines (Fig. 6a , supplementary Fig. S4-S7 ). Western blot analysis showed that overexpression or constitutive activation of YAP increased EGFR and ERBB3 protein levels in HOSE, KGN, and TOV21G cells (Fig. 6b, supplementary Fig. S8a ). We also found that YAP knockdown successfully reduced the expression of EGFR, ERBB3, HBEGF, and NRGs in TOV21G cells ( To test whether YAP also regulated ERBB receptors and ligands in vivo, we used immunofluorescent histochemistry and/or RT-PCR to determine the expression of HBEGF, NRG1, NRG2, EGFR and ERBB3 expression in human tumors xenografts (derived from TOV21G-MXIV, TOV21G-YAP & TOV21G-YAP S127A ) in the athymic nude mice. The results showed that the protein levels of EGFR and ERBB3, and the mRNA levels of HBEGF, NRG1, NRG2, EGFR, and ERBB3 were dramatically induced in tumor xenografts derived from TOV21G-YAP & TOV21G-YAP S127A cells compared with that of the control group (from TOV21G-MXIV cells) (Fig. 6c& 6d) .
We have also found that YAP regulates the expression of ERBB3 and the production of HBEGF and NRGs may depends on its interaction with transcription factor TEAD, because treatment of HOSE-MXIV, HOSE-YAP and HOSE-YAP S127A cells with 5μM verteporfin, which inhibits the interaction between YAP and TEAD, 23 significantly blocked YAPinduced mRNA expression of ERBB3, HBEGF, NRG1 and NRG2 (supplementary Fig.   S10 ). Most importantly, blocking the interaction of YAP and TEAD with verteporfin drastically reduced the production of free HBEGF in the both 2D and 3D culture system, and eliminated the secretion of NRG1 in both 2D and 3D culture system ( Supplementary  Fig. S10 ).
Interactions between YAP and ERBB pathways regulate ovarian cell proliferation
Because HBEGF specifically binds to EGFR and ERBB4, while NRG1 and NRG2 specifically bind to ERBB3 and ERBB4 to regulate cancer cell proliferation, 26 we designed experiments to determine whether these ligands and receptors are involved in YAP-mediated ovarian cancer cell growth. Treatment with recombinant human NRG1-β1 and HBEGF significantly increased TOV21G and KGN cells proliferation (Fig. 7a& 7b) . Moreover, HBEGF and NRG1-β1 also significantly stimulated proliferation of HOSE cell in a more physiological-relevant 3D handing drop culture system (Fig. 7c& 7d) .
Knockdown of HBEGF in HOSE and TOV21G cells with different YAP activity levels partially but significantly blocked YAP-induced cell proliferation ( In addition, knockdown of HBEGF or ERBB3 dramatically reversed oncogenic transformation in HOSE cells and inhibited YAP-induced enhancement of anchorageindependent growth of TOV21G cells, as indicated by a significant decrease in the colony formation induced by YAP overexpression or constitutive activation (p<0.0001) ( Fig. 8a-8d ), indicating that ERBB3 and HBEGF contribute to YAP-mediated anchorage-independent cell growth.
The interaction between the Hippo/YAP and the ERBB signaling pathways is required for HBEGF and NRG1 stimulation of ovarian cancer cell growth
In confluent TOV21G ovarian cancer cells, YAP was highly phosphorylated following serum starvation. Treatment of confluent TOV21G cancer cells with HBEGF and NRG1β1 resulted in a rapid and significant decrease in phosphorylation of LATS1, MOB1 and YAP ( Knockdown of HBEGF or ERBB3 blocked YAP-induced formation of spheroids by HOSE cells and suppressed the growth of HOSE cells in the 3D culture system (Fig. 9b) . Knockdown of YAP not only eliminated HBEGF-and NRG1β1-induced TOV21G cell proliferation, but also suppressed the basal proliferation of TOV21G. (Fig. 9c) . Similar results were observed in KGN cells (Fig. 9d) . Intriguingly, treatment of confluent TOV21G cells with HBEGF and NRG1β1 for 48 hours stimulated the transcription of ERBB3, HBEGF, NRG1, and NRG2 genes ( Supplementary Fig. S17 ). any association between YAP expression and clinical outcomes in serous cancers. In their study, correlation between nuclear YAP and poor survival is limited to patients with ovarian clear cell carcinoma. 10 The discrepancy can be attributed to the relatively small sample size in these studies. In the present study, using large cohort of patient samples, we found that total YAP staining strongly correlated with stage and TNM status (tumor, lymph node, and metastasis staging) was significantly associated with poor patient survival. Further analysis showed that total YAP staining was strongly correlated with stage and TNM status. Our results are consistent with previous reports in multiple human cancers, 28 , 31 , 32 and indicate that YAP activity may play a causal role on ovarian cancer progression and metastasis. Nevertheless, we realize the limitation of IHC-based detection and analysis systems. The utility of YAP as an independent prognostic marker of ovarian cancer needs to be extensively verified using additional approaches. Expressions of EGFR, ERBB3, HBEGF, NRG1 and NRG2 have been implicated in both normal organ development and malignancy. 26 The expression and function of EGFR and ERBB2 in breast and ovarian cancer have been extensively studied. However, roles of ERBB3 in ovarian cancer initiation and progression are not well defined. A recent study showed that in a portion (~25%) of ovarian cancers, NRG1 activated ERBB3 to promote cancer cell proliferation and drive tumor growth. 40 Consistent with this finding, in the present study, we found that NRG1 was able to promote TOV21G and KGN cell proliferation (Fig. 7a& 7b) . Interestingly, we found that overexpression of YAP or constitutively active YAP in TOV21G or KGN ovarian tumor cells dramatically induced NRG1 production and ERBB3 expression. Knockdown of ERBB3 eliminated the stimulatory effect of YAP on cancer cell proliferation (Fig. 7e& 7f) , and nearly abrogated YAP-enhanced anchorage-independent growth of TOV21G cells. These results clearly indicate that YAP has the potential to control ovarian cancer cell proliferation via regulating the NRG1/ERBB3 pathway. Intriguingly, we found that NRG1 was able to rapidly suppress Hippo pathway and activate YAP by dephosphorylating LATS1, MOB1 and YAP (Fig. 9) . Simultaneously, NRG1 also stimulated the expression of ERBB3, NRG1, NRG2, and HBEGF. Knockdown of YAP in ovarian cancer cells suppressed the basal growth in these cells and eliminated NRG1-stimulated cancer cell proliferation (Fig. 9) . Taken together, our data indicate the existence of an NRG1/ERBB3/YAP/NRG1 autocrine loop in the ovarian cancer cells. This autocrine loop appears to play a critical role in the initiation and progression of ovarian cancers.
DISCUSSION
HBEGF has been shown to play a critical role in the ovarian tumorigenesis and tumor progression. 41 In the present study, we found that overexpression or constitutive activation of YAP also increased production of free HBEGF and expression of EGFR (the selective receptor for HBEGF). Knockdown of YAP in cancer cells suppressed production of free HBEGF and expression of EGFR. Like NRG1, HBEGF also stimulated ovarian cancer cell growth. Moreover, HBEGF was able to suppressed phosphorylation of LATS1, MOB1 and YAP and stimulate production of NRG1 and free HBEGF, and expression of ERBB3. These results suggest the potential presence of a pro-proliferation HBEGF/EGFR/YAP/HBEGF autocrine loop in the ovarian cancer cells. A recent report indicates that the EGFR-RAS-MAPK signaling promotes phosphorylation of the Ajuba family protein WTIP and thus enhances WTIP binding to LATS and WW45, leading to suppression of Hippo pathway and activation of YAP 20 . This evidence strongly supports our findings. Interestingly, we found that treatment of TOV21G with HBEGF within 2 hours, but not NRG1, nearly eliminated the expression of EGFR receptor (supplementary Fig. S13 & Fig. S14 ). This observation is consistent with previous finding that HBEGF binding lead to the rapid lysosomal degradation of EGFR. 42 Therefore, HBEGF and neuregulin may regulate ovarian cancer progression in different ways: neuregulin constitutively stimulates ovarian cancer progression through a positive autocrine/paracrine loop, while HBEGF may amplify the NRG1/ERBB3/YAP/NRG1 autocrine loop.
YAP has been showed to act mainly through its direct interaction with TEAD/TEF family to regulate downstream genes expression. 5 , 6 Verteporfin is a selective antagonist of YAP functioning by interrupting YAP-TEAD interaction. 23 Our data show that verteporfin not only inhibits YAP-induced transformation of ovarian surface epithelial cells, suppressed YAP-enhanced growth of normal and ovarian cancer cells, but also blocked YAP-induced production of free HBEGF and NRG1, as well as expression of ERBB3 receptor. Clearly, YAP regulation of the initiation and progression of ovarian cancer may depend on its proper interaction with the TEAD transcription factor. Recent studies showed that beside TEAD, YAP also interacts with others transcriptional factors, such as Smad, Runx1/2, p73, Pax3, and TBX5 (a list that is still rapid growing), to regulate downstream gene expression. 5 , 6 These transcription factors may also be important for the ovarian cancer initiation and progression and need further studies.
In conclusion, our present study shows that YAP has the potential to transform the ovarian surface epithelial cells, leading to initiation and progression of ovarian cancer. YAP (potentially in a Hippo pathway dependent manner) forms autocrine loops with the ERBB signaling pathway to induced the initiation and promote the progression of ovarian cancer (Fig. 10) . Although up regulation of EGFR, ERBB2, and ERBB3 is found in 60%, 18%, and 50% of epithelial ovarian cancer tissues, respectively, the clinical trial results with single agent EGFR inhibitors such as erlotinib, getitinib, trastuzumab or pertuzumab, have proven to be of little benefit in randomized trials. 43 The identification of a NRG1/ERBB3/YAP/ NRG1 autocrine loop in ovarian cancers suggests that ERBB3 will be a promising target for ovarian cancer. MM-121, a monoclonal ERBB3-directed antibody, is currently under investigation in phase II trials. Combined targeting the Hippo/YAP pathway and ERBB pathways, especially the NRG1/ERBB3 pathway, has potential to provide a novel therapeutic strategy for ovarian cancer treatment. 
MATERIALS AND METHODS
Chemicals
Cell Lines and Human Ovarian Tissues
TOV21G, an ovarian epithelial cancer cell line, was purchased from ATCC (Manassas, VA). KGN, an ovarian granulosa cell tumor cell line, was obtained from the Riken Biosource Center (Riken Cell Bank, Ibaraki, Japan). Immortalized human normal ovarian epithelial cells (HOSE-T80) were from Dr. Bo R Reuda at Massachusetts General Hospital (Boston, MA). Human ovarian tissue microarray slides were purchased from Biomax (Rockville, MD).
Immunohistochemistry
YAP expression in ovarian tissues was detected using a peroxidase-based immunohistochemistry, the immunosignal was visualized with DAB kit (Invitrogen, Carlsbad, CA). Sections were scanned with an iSCAN Coreo Slide Scaner (Ventana Medical Systems, Inc., Oro Valley, AZ, USA). The intensity of the positive signal was quantified using Aperio ImageScope software (Aperio® Technologies, Inc., Vista, CA).
Cell Transfection
Nine cell lines were established to determine the effect of YAP on ovarian cancer cell proliferation. Briefly, HOSET80, TOV21G, and KGN cells were cultured to 40% confluent and then transfected with retrovirus-based YAP overexpression constructs (YAP, YAP S127A ) or empty vector (MXIV). Stable transfected clones were selected using G418. Cell growth was determined by counting the cell number using an Invitrogen Countess® Automated cell counter (Invitrogen Corporation, Carlsbad, CA).
Three-dimension hanging drop cell culture and Colony Formation Assays
Two three-dimension (3D) hanging drop culture systems were used to examine the role of YAP in the cell proliferation and cell-cell communication. Briefly, Cells (0.5X10 6 ) were cultured in Perfecta3D (3D Biomatrix, Ann Arbor, MI) or GravityPLUS™ 3D Cell Culture plates (InSphero, Schlieren, Switzerland) according to the company's instruction. Cytoselect 96-Well Cell Transformation assay kit (Cell Biolabs, Inc., San Diego, CA) was used to determine the effect of YAP on the anchorage-independent growth of ovarian cells.
RT-PCR and Western Blot Analysis
Total RNA was prepared by RNeasy Mini Kit (QIAGEN, Valencia, CA), and reverse transcription was completed by using SuperScript First-Strand kit (Life TechnlogyTM, Grand Island, NY). RT-PCR was run on MJ PTC100 Programmable Thermal cycler (BioRadLaboratories, Hercules, CA) with a protocol established in our laboratory. 44 , 45 The primers have been validated previously. 46 Protein levels were determined with Western Blot with a protocol established in our laboratory. 44 , 45 The immunosignal was detected by using
The SuperSignal West Femto Chemiluminescent Substrate Kit (Pierce/Thermo Scientific, Rockford, IL); the images were captured and analyzed with a UVP gel documentation system (UVP, LLC, Upland, CA).
In Vivo Tumorigenicity 5X10 6 cells / 0.1 mL PBS were injected subcutaneously into the dorsal flank of 7-week-old female athymic nude mice (n=5). Tumor volume (mm 3 ) was calculated as follows: volume = (shortest diameter) 2 x (longest diameter) X 3.14 ÷ 6. The animal handling procedures and all experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Nebraska Medical Center.
Immunofluorescent Histochemistry (IF)
Frozen sections at 6 μm were stained with a protocol established in our laboratory. 44 , 45 Images were captured using a Zeiss 710 Meta Confocal Laser Scanning Microscope and analyzed using the Zeiss Zen 2010 software (Carl Zeiss Microscopy, LLC, Thornwood, NY). TUNEL assay was performed using TUNEL Apoptosis Detection kit (EMD Millipore, inc. Darmstadt, Germany) to determine cell apoptosis.
Statistical Analysis
All experiments were repeated at least three times unless otherwise noted. Statistical analyses were conducted primarily using GraphPad Prism software (GraphPad Software, Inc.). Data were analyzed for significance by one-way ANOVA with Tukey's post-Hoc test. A value of p< 0.05 was considered to be significant.
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